wholegenom
sequenc
wg
pathogen
becom
increasingli
import
basic
research
also
clinic
scienc
practic
virolog
wg
import
develop
novel
treatment
vaccin
increas
power
molecular
epidemiolog
evolutionari
genom
opinion
articl
suggest
wg
virus
clinic
set
becom
increasingli
import
patient
care
give
overview
differ
wg
method
use
virolog
summar
advantag
disadvantag
although
partial
address
technic
financi
ethic
issu
regard
clinic
applic
viral
wg
techniqu
provid
import
insight
viru
transmiss
evolut
pathogenesi
natur
review
microbiolog
volum
march
perspect
c
l
l
n
p
u
b
l
h
e
r
l
e
p
r
f
p
r
n
g
e
r
n
u
r
e
l
l
r
g
h
r
e
e
r
v
e
charlott
j
houldcroft
sinc
public
first
shotgunsequenc
genom
cauliflow
mosaic
viru
draft
human
genom
first
bacteri
genom
haemophilu
influenza
mycoplasma
genitalium
enabl
rapidli
decreas
cost
highthroughput
sequenc
genom
chang
understand
human
pathogen
biolog
sever
larg
project
aim
systemat
analys
microbi
genom
recent
complet
ongo
exampl
sequenc
thousand
microbiom
fungal
genom
project
shape
knowledg
genet
variat
present
pathogen
popul
genet
chang
underli
diseas
divers
microorgan
share
environ
method
data
wholegenom
sequenc
wg
develop
basic
scientif
research
increasingli
appli
clinic
medicin
involv
human
pathogen
exampl
wg
use
identifi
new
rout
transmiss
mycobacterium
abscessu
healthcar
facil
nosocomi
transmiss
understand
neisseria
meningitidi
epidem
africa
wherea
sequenc
tabl
import
deepli
sequenc
viral
pathogen
also
explor
two
area
viral
wg
recent
proven
clinic
util
metagenom
sequenc
identifi
virus
caus
enceph
box
role
wg
molecular
epidemiolog
public
health
manag
panamerican
zika
viru
outbreak
box
final
briefli
consid
ethic
data
analysi
challeng
clinic
viral
wg
present
small
virus
hiv
influenza
viru
hepat
b
viru
hbv
hepat
c
viru
hcv
sequenc
partial
genom
wide
use
research
also
import
clinic
applic
one
main
applic
reason
sequenc
virus
detect
drug
resist
exampl
manag
highli
activ
antiretrovir
therapi
haart
hiv
reli
viral
sequenc
detect
drugresist
variant
haart
substanti
improv
surviv
patient
hiv
success
therapi
requir
longterm
suppress
viral
replic
antiretrovir
drug
may
prevent
impair
host
immun
suboptim
drug
penetr
certain
tissu
compart
incomplet
adher
therapi
viral
replic
continu
despit
treatment
high
mutat
rate
hiv
enabl
resist
variant
develop
becom
standard
practic
mani
part
world
sequenc
hiv
pol
gene
encod
main
viral
enzym
detect
variant
confer
resist
inhibitor
revers
transcriptas
integras
proteas
particularli
patient
first
diagnos
viral
load
indic
treatment
failur
sequenc
resist
variant
enabl
target
chang
treatment
result
greater
reduct
viral
load
standard
care
undetect
hiv
load
versu
patient
six
month
thu
sequenc
resist
variant
guid
hiv
treatment
improv
diseas
outcom
similar
approach
use
identifi
resist
variant
hcv
hbv
influenza
viru
partial
genom
use
detect
drug
resist
rna
virus
influenza
viru
dna
virus
human
cytomegaloviru
hcmv
viral
genom
sequenc
becom
ever
import
especi
clinic
research
epidemiolog
wg
pathogen
advantag
detect
known
drugresist
variant
singl
test
wherea
deep
sequenc
sequenc
high
coverag
identifi
low
level
drugresist
variant
enabl
intervent
resist
becom
clinic
appar
whole
genom
also
provid
good
data
identifi
link
infect
public
health
infect
control
purpos
howev
progress
use
viral
wg
clinic
practic
slow
contrast
wg
bacteria
well
accept
particularli
track
outbreak
manag
nosocomi
transmiss
antimicrobialresist
bacteria
opinion
articl
address
challeng
opportun
make
wg
use
modern
nextgener
sequenc
ng
method
standard
practic
clinic
virolog
discuss
strength
weak
technic
challeng
differ
viral
wg
method
sequenc
whole
genom
limit
sequenc
small
number
gene
encod
target
antivir
agent
hiv
pol
norm
clinic
practic
detect
limit
number
antiviralresist
variant
wg
costli
labourintens
use
compar
sequenc
specif
gene
target
drug
howev
increas
number
resist
gene
locat
across
viral
genom
togeth
decreas
cost
sequenc
use
sequenc
data
transmiss
studi
drive
reapprais
need
wg
exampl
antivir
treatment
hcv
target
four
gene
product
pcr
reaction
increas
chanc
failur
requir
start
materi
labour
intens
gener
less
tractabl
diagnost
use
sequenc
whole
genom
simultan
captur
resist
variant
remov
need
design
optim
pcr
assay
detect
resist
new
drug
good
exampl
hcmv
wg
simultan
captur
gene
encod
target
licens
therapi
unknown
function
dna
polymeras
serin
threonin
protein
kinas
newer
drug
letermovir
target
terminas
complex
enabl
comprehens
antiviralresist
test
singl
test
addit
wg
provid
inform
antigen
epitop
viru
evolut
patient
time
evid
recombin
hcmv
strain
wg
also
detect
put
novel
drugresist
variant
predict
chang
epitop
although
phenotyp
test
variant
requir
confirm
clinic
resist
map
epitop
chang
preexist
resist
antivir
drug
increas
exampl
hcv
resist
proteas
inhibitor
hbv
resist
nucleosid
analogu
reversetranscriptas
inhibitor
wg
provid
comprehens
resist
data
requir
select
appropri
treatment
complet
knowledg
resist
variant
also
support
novel
decis
clinic
manag
exampl
identif
extens
genomewid
hcmv
drug
resist
patient
support
decis
treat
individu
autolog
cytomegalovirusspecif
cell
instead
antivir
drug
wg
may
also
better
identifi
transmiss
event
outbreak
alway
possibl
sequenc
subgenom
fragment
exampl
wg
respiratori
syncyti
viru
rsv
identifi
variat
outsid
gene
tradit
use
genotyp
inform
could
use
track
outbreak
household
genet
variabl
singl
gene
low
transmiss
studi
numer
phylogenet
inform
variant
site
obtain
fulllength
near
fulllength
genom
remov
need
highqual
sequenc
enabl
robust
link
case
ebola
viru
infect
public
health
intervent
real
time
epidem
gene
encompass
viral
genom
individu
sequenc
gene
expens
timeconsum
wg
partialgenom
sequenc
particularli
problemat
larg
viral
genom
particular
herpesvirus
hcmv
varicella
zoster
viru
vzv
herp
simplex
viru
ref
virus
tradit
treat
drug
target
viral
thymidin
serinethreonin
protein
kinas
dna
polymeras
howev
increas
number
drug
develop
interact
differ
protein
encod
viral
gene
scatter
across
genom
mean
target
sequenc
resist
test
costli
involv
routin
use
pathogen
wg
diagnost
purpos
like
wider
clinic
research
benefit
exampl
zika
viru
sequenc
gener
epidemiolog
purpos
inform
public
health
decis
addit
hiv
genom
sequenc
identifi
antiviralresist
variant
also
use
studi
viru
evolut
viral
genet
associ
diseas
includ
genotypephenotyp
associ
studi
genometogenom
associ
studi
look
associ
viral
genet
variant
host
genet
variant
outcom
infect
viral
load
set
point
hiv
infect
need
deep
sequenc
modern
method
use
massiv
parallel
sequenc
enabl
better
examin
divers
analysi
viru
popul
contain
nucleotid
variant
haplotyp
low
frequenc
less
consensu
sequenc
minor
variant
analysi
particularli
power
rna
virus
reversetranscrib
dna
virus
retrovirus
typic
show
high
divers
even
singl
host
hiv
classic
exampl
revers
transcriptas
hiv
errorpron
introduc
mutat
genotyp
predict
maraviroc
treatment
failur
subconsensu
frequenc
hiv
also
import
success
failur
bone
marrow
transplant
donor
inform
may
influenc
decis
stop
antivir
therapi
patient
minor
variant
identif
haplotyp
also
use
detect
mix
infect
infect
differ
hcmv
genotyp
superinfect
associ
poor
clinic
outcom
detect
mix
infect
wg
might
justifi
aggress
treatment
sanger
sequenc
viru
popul
detect
minor
variant
frequenc
wherea
ng
sequenc
pcr
amplicon
much
greater
depth
consequ
captur
variabl
present
sensit
specif
specif
analys
viru
sequenc
method
mani
studi
drug
resist
hiv
use
deepsequenc
pcr
amplicon
requir
minor
variant
present
decreas
possibl
falseposit
result
may
miss
drugresist
mutat
frequenc
lead
poor
treatment
outcom
although
frequenc
threshold
lower
may
clinic
relev
detect
drug
resist
hiv
less
clear
whether
degre
sensit
requir
monitor
vaccin
escap
hbv
drug
resist
herpesvirus
discuss
larg
cohort
patient
need
test
treatment
establish
threshold
minor
drugresist
variant
vaccineescap
variant
clinic
relev
viru
direct
deep
sequenc
clinic
materi
either
shotgun
method
rnaseq
method
call
metagenom
method
also
enabl
unbias
detect
diagnosi
pathogen
provid
altern
cultur
electron
microscopi
quantit
pcr
qpcr
see
sequenc
viral
nucleic
acid
whether
cultur
directli
clinic
specimen
complic
presenc
contamin
host
dna
contrast
bacteri
sequenc
current
carri
clinic
isol
cultur
thu
sampl
prepar
compar
straightforward
tabl
extrem
high
rate
per
base
per
cell
mani
close
relat
subtli
differ
viral
variant
exist
singl
patient
variant
sometim
describ
quasispeci
cloud
intrahost
viru
divers
presenc
mix
popul
virus
introduc
problem
determin
true
consensu
major
sequenc
minor
nonconsensu
variant
may
also
chang
clinic
phenotyp
viru
use
predict
chang
genotyp
tropism
drug
resist
exampl
minor
variant
confer
drug
resist
hiv
present
sequenc
read
patient
baselin
rapidli
becom
major
consensu
variant
select
pressur
drug
treatment
similar
chang
frequenc
resistanceassoci
allel
treatment
observ
hbv
hcv
hcmv
influenza
viru
deep
sequenc
virus
requir
detect
drug
resist
also
key
genotyp
predict
receptor
tropism
hiv
treatment
implic
hiv
group
use
cellular
coreceptor
use
ccchemokin
receptor
use
cxc
chemokin
receptor
dual
tropism
maraviroc
antagonist
block
infect
hiv
hiv
frequenc
case
enceph
unknown
origin
metagenom
techniqu
promis
diagnost
tool
variou
protocol
use
main
method
use
rna
sequenc
rnaseq
metagenom
rnaseq
total
rna
subset
rna
extract
sampl
exampl
cerebrospin
fluid
brain
biopsi
convert
complementari
dna
cdna
sequenc
metagenom
gener
describ
procedur
dna
may
also
includ
simultan
sequenc
dna
rna
incorpor
cdnasynthesi
step
rnaseq
may
improv
detect
pathogen
virus
mani
virus
rna
genom
viral
mrna
cerebrospin
fluid
csf
brain
indic
presenc
viru
viral
gene
transcrib
howev
dna
virus
experi
lowlevel
transcript
may
poorli
detect
use
rnaseq
read
number
dna
virus
may
higher
metagenom
dataset
method
success
identifi
new
known
viral
pathogen
case
enceph
unknown
origin
metagenom
use
aid
diagnosi
character
enteroviru
case
acut
flaccid
paralysi
metagenom
identifi
herpesvirus
csf
four
patient
suspect
viral
meningoenceph
rnaseq
also
identifi
herp
simplex
viru
patient
enceph
although
use
dnase
digest
intend
decreas
amount
host
nucleic
acid
decreas
number
read
mump
vaccin
viru
also
detect
patient
chronic
enceph
use
rnaseq
rnaseq
success
identif
enceph
caus
astrovirus
coronavirus
death
three
squirrel
breeder
enceph
link
novel
squirrel
bornaviru
identifi
separ
metagenom
sequenc
dna
rna
metagenom
provid
inform
viru
sampl
pcr
alon
may
import
molecular
epidemiolog
wherea
rnaseq
identifi
viral
sequenc
viral
gene
express
review
ref
current
genom
sequenc
virus
achiev
ultradeep
sequenc
enrich
viral
nucleic
acid
sequenc
either
directli
concentr
viru
particl
approach
cost
complex
three
main
method
current
use
viral
genom
sequenc
metagenom
sequenc
pcr
amplicon
sequenc
target
enrich
sequenc
fig
metagenom
approach
use
extens
pathogen
discoveri
character
microbi
divers
environment
clinic
sampl
total
dna
andor
rna
includ
host
bacteria
virus
fungi
pathogen
extract
sampl
librari
prepar
sequenc
shotgun
sequenc
rna
sequenc
rnaseq
box
explor
diagnost
applic
metagenom
rnaseq
exampl
enceph
unknown
aetiolog
convent
method
pcr
often
diagnost
metagenom
rnaseq
detect
viral
infect
dna
cdna
amplifi
fragment
length
polymorph
aflp
abbrevi
vidisca
filtrat
ultracentrifug
deplet
free
nucleic
acid
mostli
come
host
tri
howev
method
may
also
decreas
total
amount
viral
nucleic
acid
insuffici
prepar
sequenc
librari
nonspecif
amplif
method
multipl
displac
amplif
mda
make
use
random
primer
polymeras
increas
dna
yield
howev
approach
time
consum
costli
may
increas
risk
bias
error
contamin
without
necessarili
improv
sensit
moreov
proport
host
read
often
remain
high
metagenom
method
use
pathogen
discoveri
diagnosi
crucial
use
appropri
bioinformat
tool
databas
evalu
whether
detect
pathogen
sequenc
like
caus
infect
incident
find
contamin
bioinformat
analys
larg
metagenom
dataset
requir
highperform
comput
resourc
fact
metagenom
requir
prior
knowledg
viral
genom
consid
advantag
enabl
novel
virus
sequenc
without
need
primer
probe
design
synthesi
particularli
relev
rapid
respons
emerg
threat
zika
viru
virusassoci
cancer
metagenom
inform
clinic
care
provid
inform
cancer
evolut
gener
highcoverag
data
integr
viru
genom
howev
incident
find
host
microbi
sequenc
may
also
present
ethic
even
diagnost
dilemma
clinic
metagenom
see
recent
exampl
involv
cluster
case
acut
flaccid
myeliti
associ
enteroviru
ref
metagenom
data
sampl
taken
patient
show
presenc
altern
pathogen
treatabl
debat
formal
inform
scientif
channel
see
omicsom
blogspot
articl
regul
report
framework
import
resolv
futur
issu
kind
altern
metagenom
approach
enrich
specif
viral
genom
sequenc
pcr
amplif
viral
genet
materi
use
primer
complementari
caus
enceph
addit
method
use
sequenc
whole
genom
virus
includ
epsteinbarr
viru
ebv
hcv
howev
clinic
specimen
presenc
contamin
nucleic
acid
host
commens
microorgan
tabl
decreas
sensit
proport
read
match
target
viru
genom
metagenom
wg
often
low
exampl
ebv
blood
healthi
adult
lassa
viru
clinic
sampl
zika
viru
sampl
enrich
viru
particl
filtrat
centrifug
read
depth
often
inadequ
detect
resist
cost
high
thu
metagenom
sequenc
typic
carri
small
number
sampl
research
purpos
concentr
viru
particl
see
zika
viru
exampl
deplet
host
materi
andor
sequenc
high
read
depth
increas
amount
viru
sequenc
method
add
cost
concentr
viru
particl
clinic
specimen
antibodymedi
pulldown
exampl
viru
discoveri
base
complementari
wholegenom
sequenc
wg
zika
viru
help
understand
epidemiolog
recent
outbreak
south
america
includ
origin
spread
viru
connect
viru
microcephali
also
inform
control
measur
stop
import
zika
case
disrupt
transmiss
reservoir
blood
safeti
measur
hospit
flavivirus
zika
viru
wg
least
near
wholegenom
sequenc
requir
provid
molecular
epidemiolog
studi
suffici
power
wg
phylogenet
analysi
molecular
clock
date
combin
epidemiolog
data
use
studi
introduct
zika
viru
south
america
exampl
recent
common
ancestor
strain
circul
brazil
predat
footbal
world
cup
make
highli
unlik
event
respons
introduct
asianlineag
zika
viru
south
america
wg
also
central
understand
pathogenesi
zika
viru
exampl
tri
identifi
sequenc
chang
associ
microcephali
current
unclear
genom
region
determin
pathogenesi
like
numer
wholegenom
sequenc
zika
viru
around
world
individu
microcephali
asymptomat
infect
requir
link
particular
mutat
birth
defect
far
chang
zika
viru
genom
unambigu
associ
microcephali
wg
fragment
sequenc
use
identifi
case
zika
viru
transmiss
platelet
transfus
case
suggest
asymptomat
donor
transmit
viru
immunocompromis
individu
pcrbase
test
alreadi
establish
presenc
zika
viru
blood
suppli
previou
outbreak
infect
detect
recipi
blood
product
base
new
evid
blood
product
may
need
screen
routin
zika
viru
final
wg
zika
viru
isol
identifi
sequenc
polymorph
primer
bind
site
may
make
pcrbase
diagnosi
quantif
viral
load
difficult
highlight
need
character
populationlevel
divers
especi
epidem
local
circul
viru
may
diverg
virus
locat
time
period
sever
project
underway
determin
populationlevel
divers
includ
zika
brazil
real
time
analysi
zibra
mobil
laboratori
project
use
portabl
metagenom
sequenc
zika
viru
realtim
report
result
known
nucleotid
sequenc
common
approach
enrich
small
viral
genom
hiv
influenza
viru
recent
exampl
pcr
amplicon
enrich
follow
wg
includ
phylogenet
analysi
measl
viru
outbreak
winter
olymp
track
recent
ebola
viru
zika
viru
box
epidem
pcr
amplicon
wg
noroviru
genom
size
kb
use
understand
viru
transmiss
commun
hospit
set
reveal
independ
introduct
pathogen
hospit
nosocomi
transmiss
despit
measur
control
infect
pcrbase
deepsequenc
studi
gener
sever
whole
genom
influenza
viru
kb
dengu
viru
kb
hcv
kb
feasibl
virus
rel
small
genom
requir
pcr
amplicon
assembl
wholegenom
sequenc
howev
pcr
product
respect
clinic
applic
problemat
high
laboratori
workload
associ
numer
discret
pcr
reaction
necess
individu
normal
concentr
differ
pcr
amplicon
pool
increas
probabl
reaction
failur
due
primer
mismatch
particularli
highli
variabl
virus
high
cost
labour
consum
therefor
although
pcrbase
sequenc
virus
larg
kb
technic
possibl
proport
relationship
genom
size
technic
complex
make
pcrbase
sequenc
viral
genom
kb
impract
current
technolog
particularli
larg
multisampl
studi
routin
diagnost
anoth
consider
increas
number
pcr
reaction
requir
correspond
increas
sampl
amount
alway
possibl
clinic
specimen
limit
improv
microfluid
technolog
may
help
overcom
barrier
exampl
fluidigm
raindanc
droplet
sequenc
technolog
microfluidicsbas
pcr
pool
multipl
amplicon
use
success
sequenc
sever
antimicrobialresist
loci
exampl
microbiom
pig
also
use
viral
genom
potenti
singlegenom
level
highli
variabl
pathogen
particularli
wide
diverg
genet
lineag
genotyp
hcv
noroviru
caus
problem
pcr
amplif
primer
amplif
primer
mismatch
care
primer
design
may
help
mitig
problem
novel
variant
remain
problemat
target
enrich
method
target
enrich
also
known
pulldown
captur
specif
enrich
method
use
sequenc
whole
viral
genom
directli
clinic
sampl
without
need
prior
cultur
pcr
method
typic
involv
small
rna
dna
probe
complementari
pathogen
refer
sequenc
panel
refer
sequenc
unlik
specif
pcr
ampliconbas
method
reaction
carri
singl
tube
contain
overlap
probe
cover
whole
genom
hybrid
reaction
probe
bound
solid
phase
exampl
streptavidinlabel
heterogen
rna
virus
hcv
noroviru
rabi
viru
rsv
may
necessit
use
multipl
overlap
set
primer
ensur
amplif
genotyp
pcr
amplicon
sequenc
success
wg
sampl
low
viru
concentr
metagenom
method
although
method
target
enrich
viral
sequenc
may
work
equal
well
sampl
shown
noroviru
sampl
overlap
pcr
combin
ng
use
sequenc
whole
genom
larger
virus
hcmv
method
limit
scalabl
mani
primer
rel
larg
amount
start
dna
requir
limit
number
suitabl
sampl
avail
also
genom
studi
use
method
exampl
pcr
product
requir
amplifi
genom
ebola
viru
two
studi
noroviru
need
ref
reaction
carri
singl
well
similarli
microfluidicsbas
pcr
amen
highthroughput
autom
lack
cultur
step
mean
sequenc
obtain
repres
origin
viru
rather
cultur
viru
isol
fewer
mutat
pcramplifi
templat
success
method
depend
avail
refer
sequenc
viru
interest
specif
increas
probe
design
larger
panel
refer
sequenc
lead
better
captur
concentr
metagenom
proport
sequenc
data
map
pathogen
unenrich
clinic
sampl
small
target
enrich
increas
percentag
ontarget
viral
read
improv
qualiti
depth
sequenc
result
enabl
sampl
sequenc
per
run
unenrich
metagenom
librari
equival
ontarget
sequenc
perform
improv
also
decreas
price
sequenc
although
cost
librari
prepar
increas
altern
approach
enrich
viral
read
includ
pulsedfield
gel
electrophoresi
pfge
separ
larg
viral
genom
smaller
fragment
host
dna
enrich
techniqu
use
degener
rna
dna
probe
captur
hundr
viral
speci
also
develop
exampl
virom
captur
sequenc
vircapseq
method
design
detect
known
novel
virus
although
perform
remain
evalu
date
littl
direct
comparison
three
method
viral
genom
sequenc
clinic
practic
one
paper
evalu
rel
perform
sequenc
hcv
result
studi
three
differ
enrich
protocol
two
metagenom
method
one
overlap
pcr
method
evalu
show
metagenom
method
least
sensit
yield
lowest
genom
coverag
compar
sequenc
effort
prone
result
incomplet
genom
assembl
pcr
method
requir
repeat
amplif
like
miss
mix
infect
reaction
success
result
consist
read
depth
wherea
read
depth
proport
viru
copi
number
metagenom
target
enrich
pcr
gener
incomplet
sequenc
hcv
genotyp
particularli
genotyp
metagenom
target
enrich
target
enrich
consist
method
result
full
genom
ident
consensu
sequenc
eas
librari
prepar
metagenom
target
enrich
sequenc
hcv
consid
major
advantag
clinic
applic
pcr
may
still
appropri
sampl
low
viral
load
divers
sampl
target
enrich
possibl
despit
small
mismatch
templat
probe
howev
wherea
pcr
amplif
requir
knowledg
flank
region
target
region
target
enrich
requir
knowledg
intern
sequenc
design
probe
howev
one
probe
fail
intern
overlap
region
may
still
captur
probe
target
enrich
suitabl
character
novel
virus
low
homolog
known
virus
metagenom
case
pcr
use
degener
primer
mix
similar
variabl
primer
may
appropri
method
techniqu
constrain
start
viru
concentr
although
virus
could
sequenc
sampl
viral
load
low
intern
unit
iu
ml
hcv
iu
ml
hcmv
reduc
depth
coverag
sequenc
data
lower
viru
figur
method
sequenc
viral
genom
clinic
specimen
specimen
origin
compris
mix
host
blue
pathogen
red
dna
sequenc
pathogen
rna
genom
rna
sampl
convert
complementari
dna
cdna
pcr
librari
prepar
direct
metagenom
sequenc
provid
accur
represent
sequenc
sampl
although
high
sequenc
data
analysi
storag
cost
pcr
amplicon
sequenc
use
mani
discret
pcr
reaction
enrich
viral
genom
increas
workload
larg
genom
substanti
decreas
cost
target
enrich
sequenc
use
virusspecif
nucleotid
probe
bound
solid
phase
bead
enrich
viral
genom
singl
reaction
reduc
workload
increas
cost
librari
prepar
compar
pcr
similar
result
achiev
studi
compar
pcr
amplicon
sequenc
target
enrich
sequenc
noroviru
target
enrich
sequenc
whole
viral
genom
could
sequenc
sampl
wherea
pcrbase
capsid
sequenc
possibl
sampl
owe
low
viru
titr
pcr
primer
mismatch
suggest
target
enrich
sensit
pcr
sequenc
noroviru
better
accommod
betweenstrain
sequenc
heterogen
target
enrich
also
use
sampl
low
viral
load
incomplet
genom
coverag
metagenom
sequenc
metagenom
target
enrich
sequenc
use
pathogen
genom
size
wherea
pcrbase
method
less
suitabl
larg
viral
genom
nonvir
bacteri
fungal
parasit
genom
direct
comparison
differ
method
import
determin
method
use
base
sensit
specif
well
factor
cost
scalabl
turnaround
time
particularli
import
clinic
applic
tabl
beyond
technic
challeng
viral
wg
mention
sever
roadblock
may
slow
advanc
wg
clinic
may
consid
three
group
ethic
issu
includ
incident
host
microbiolog
find
regulatori
issu
establish
standard
good
laboratori
practic
sensit
specif
threshold
sequenc
analyt
issu
regard
data
interpret
numer
choic
analysi
option
mani
clinic
test
exampl
magnet
reson
imag
mri
scan
sequenc
genom
patient
risk
detect
diseas
associ
part
origin
investig
might
clinic
import
individu
famili
incident
find
remain
topic
intens
medic
ethic
debat
risk
incident
find
pathogen
sequenc
exampl
discoveri
hiv
infect
metagenom
sequenc
pathogen
novel
solut
issu
sensit
contamin
especi
import
wg
risk
falseneg
falseposit
detect
pathogen
highli
sensit
sequenc
whether
metagenom
pcrbase
target
enrichmentbas
may
detect
lowlevel
contamin
viral
nucleic
acid
exampl
murin
leukaemia
viru
parvoviruslik
sequenc
two
mani
contamin
come
common
laboratori
reagent
nucleic
acid
extract
column
highli
sensit
technolog
robust
laboratori
practic
protocol
requir
minim
contamin
also
import
rememb
detect
viral
nucleic
acid
necessarili
identifi
caus
ill
good
practic
use
ng
method
diagnosi
viral
infect
confirm
find
altern
independ
method
reli
test
nucleic
acid
exampl
case
enceph
unknown
origin
posit
ng
find
confirm
immunohistochem
analysi
affect
tissu
identif
viru
electron
microscopi
tissu
cultur
standard
method
includ
bioinformat
key
success
ng
wg
clinic
virolog
softwar
packag
use
graphic
user
interfac
gui
prefer
tool
requir
commandlin
expertis
strict
version
control
softwar
analysi
pipelin
requir
ensur
result
reproduc
make
best
practic
easili
shareabl
enabl
accredit
analysi
softwar
howev
bestpractic
analysi
method
continu
evolv
prematur
standard
best
practic
overli
rigid
manner
may
inhibit
innov
commerci
regul
may
help
provid
financi
regulatori
incent
ensur
analysi
tool
technolog
meet
clinic
need
final
develop
wellcur
databas
show
variant
truli
indic
drug
resist
crucial
accur
clinic
interpret
databas
alreadi
creat
hiv
hbv
hcv
without
recognit
valu
fund
agenc
correspond
central
fund
ensur
continu
mainten
upkeep
databas
associ
tool
may
becom
swiftli
outdat
unus
clinic
virolog
laboratori
use
multiplex
pcr
suppress
result
request
jb
unpublish
observ
unit
kingdom
clinic
virologist
interpret
test
result
part
team
manag
patient
may
decid
discuss
unexpect
result
physician
charg
incident
host
genet
find
exampl
detect
variant
predispos
cancer
develop
pathogen
metagenom
analysi
report
individu
unit
kingdom
permiss
consent
patient
regard
host
viru
incident
find
target
enrich
pcr
advantag
provid
result
pathogen
interest
ethic
privaci
concern
associ
presenc
host
genet
data
public
avail
metagenom
dataset
well
review
repres
separ
challeng
regulatori
challeng
regul
well
help
address
ethic
concern
also
import
standard
wg
virus
framework
requir
make
viral
wg
suffici
robust
reproduc
clinic
practic
come
sever
area
framework
laboratori
accredit
benchmark
test
alreadi
avail
exampl
clinic
laboratori
improv
amend
clia
regul
usa
accredit
accord
medic
laboratori
qualiti
compet
standard
criteria
iso
support
develop
viral
wg
standard
provid
suffici
need
pressur
implement
clinic
viral
wg
lesson
learn
use
pcr
diagnost
may
use
start
ensur
good
clinic
laboratori
molecular
practic
mean
includ
neg
sampl
everi
sequenc
run
assess
contamin
threshold
spike
sampl
known
viru
provid
sensit
threshold
includ
posit
control
control
batchtobatch
variat
increas
sequenc
cost
like
deter
adopt
pathogen
genom
sequenc
laboratori
sequenc
small
batch
sampl
central
viru
wg
help
ensur
mainten
adequ
standard
process
larg
batch
sampl
reduc
cost
although
good
reason
sequenc
whole
genom
gener
use
ng
diagnost
hospitalbas
laboratori
persuad
transit
away
sequenc
subgenom
fragment
need
see
benefit
addit
inform
patient
care
practic
feasibl
wg
includ
wg
workflow
scalabl
automat
subgenom
fragment
sequenc
suitabl
regulatori
framework
price
sequenc
whole
genom
competit
sequenc
fragment
current
cost
sequenc
viral
genom
despit
small
size
remain
higher
cost
sequenc
subgenom
resist
gene
cost
differ
sequenc
target
region
whole
viru
genom
larg
govern
size
genom
versu
size
number
target
loci
addit
wholegenom
inform
may
provid
import
addit
knowledg
discuss
futur
hold
current
ng
technolog
base
around
illumina
ion
torrent
sanger
methodolog
gener
shortread
data
present
challeng
haplotyp
phase
determin
whether
genet
variant
whether
interhost
intrahost
occur
genet
background
singl
viral
genom
clonal
relat
highli
similar
differ
genet
background
popul
sometim
call
viral
swarm
cloud
furthermor
repetit
region
recombin
difficult
resolv
use
short
read
owe
problem
map
ambigu
clinic
implic
understand
whether
exampl
multidrugresist
variant
occur
togeth
singl
viral
genom
distribut
mix
popul
virus
differ
drugresist
profil
current
unclear
although
comput
tool
help
resolv
issu
new
technolog
gener
longer
read
newer
singlemolecul
sequenc
pacbio
pacif
bioscienc
minion
oxford
nanopor
capabl
extrem
longread
sequenc
whole
viral
genom
exampl
virus
genom
less
kb
size
ebola
viru
noroviru
influenza
viru
could
theoret
obtain
select
deplet
dna
certain
methyl
pattern
similar
method
exist
far
viral
sequenc
viral
wg
increas
clinic
import
diagnosi
diseas
manag
molecular
epidemiolog
infect
control
sever
method
avail
achiev
wg
virus
clinic
sampl
amplicon
sequenc
target
enrich
metagenom
current
choic
method
specif
viru
clinic
question
metagenom
sequenc
appropri
diagnost
sequenc
unknown
poorli
character
virus
pcr
amplicon
sequenc
work
well
short
viral
genom
low
divers
primer
bind
site
target
enrich
work
pathogen
size
particularli
advantag
larg
virus
virus
divers
wellcharacter
genom
two
obviou
area
innov
current
exist
method
effect
deplet
host
dna
without
affect
viral
dna
develop
longread
technolog
achiev
flexibl
competit
price
shortread
technolog
new
technolog
requir
unit
strength
differ
method
enabl
healthcar
provid
invest
singl
technolog
suitabl
viral
wg
applic
singl
read
minion
also
advantag
fast
take
littl
four
hour
go
sampl
receipt
report
analys
data
result
betterestablish
pacbio
technolog
promis
includ
recent
report
mean
read
length
bp
pseudorabi
viru
doublestrand
dna
genom
around
kb
length
kb
read
achiev
use
pacbio
hcv
although
kb
kb
genom
preamplifi
pcr
drawback
ng
singlemolecul
sequenc
need
high
coverag
minim
effect
sequenc
error
particularli
problemat
studi
drug
resist
drug
resist
frequent
result
singlenucleotid
mutat
small
delet
base
especi
lowerfidel
rna
virus
achiev
high
coverag
necessari
ensur
accur
variant
type
challeng
lot
host
dna
compar
viral
sequenc
error
profil
technolog
make
point
mutat
particularli
hard
detect
time
write
minion
sequenc
pore
chemistri
raw
high
qualiti
call
read
read
error
rate
around
j
quick
person
commun
compar
unfavour
error
rate
technolog
illumina
ion
torrent
pacbio
singl
pass
although
accuraci
improv
use
circular
consensu
read
sequenc
howev
combin
longread
technolog
target
enrich
provid
potenti
way
forward
ambigu
resolv
suffici
depth
sequenc
achiev
target
pathogen
error
rate
methodolog
may
decreas
technolog
analyt
improv
deplet
nucleic
acid
host
altern
solut
higher
proport
viru
read
would
recov
sequenc
run
although
alreadi
solut
place
achiev
bacteri
sequenc
exampl
deplet
human
ribosom
rna
mitochondria
